Tag Cloud
-
aging
allergens
allergies
alopecia
Alzheimer
Alzheimer's
amino acid
appetite
asthma
avian flu
back
bird flu
brain
calcium
cancer
charge
child
Clinical trials
cure
damages
device
diabetes
Diet
disabilities
disease
diseases
drugs
fat
flu
food
gene
genes
Genetic
hair
Health
Health News
heart
heart disease
ibuprofen
implantation
influence
Influenza
Insulin
intelligence
lifestyle
lungs
Medications
Medications Online
medicine
memory
men health
menopause
mortality
nerve
Neuroscience
obesity
Operations
Order Medications
Order Medications Online
pain
phosphate
postmenopause
pregnancy
psychology
researc
research
sclerosis
skin
skin cancer
social
Statins
stem cells
stomach
stomach ulcer
stroke
study
sugar levels
Surgery
Surgical
tea
treatment
treatments
weather
weight
weight loss
WHO
woman's health
women
Working
Categories
Archives
- June 2010
- March 2010
- February 2010
- December 2009
- November 2009
- October 2009
- September 2009
- November 2008
- September 2008
- August 2008
Blogroll
-
Acomplia (Rimonabant)
Acutane (Isotretinoin) Acne Treatment
MedlinePlus: Health Topics
Rimonabant (Accomplia)
Trusted-Medicine.net
WebMD – Better information. Better health
Meta
Found a cure for skin cancer
November 13, 2009
Found a cure for skin cancer
Scientists have developed a new drug that helps in the treatment of the most deadly types of skin cancer, including the most recent stages.
Malignant melanoma – one of the fastest growing types of cancer. Main reason for it – the solar radiation. According to the results of preliminary tests, the drug while still under development and which bears the name of PLX4032 (R7204), can provide a long life expectancy.
Pharmaceutical companies Roche and Plexxikon announced the results of their research at the annual convention of the American Society of Clinical Oncology. PLX4032 (R7204) finds and destroys tumor cells carry the mutation type BRAF, which is present in 60% of malignant melanomas. This can help not only reduce the number of malignant tumors, but also slow the spread of cancer.
Clinical trials
Currently, only 5% of people live more than two years after the appearance of metastases. In the first phase of a clinical study in 16 patients receiving the drug PLX4032 (R7204) was found to decrease proliferation of tumor cells by at least 30%.
On average, these patients have stopped the cancer cells to spread about half a year, while more than half of the tumors were markedly reduced. Representatives of the companies Roche and Plexxikon reported that they are going to conduct a more extensive clinical trials to determine how toxic the drug may be and what should be its optimal dose.
Both companies also hope to develop a process of testing for the diagnosis of patients with melanoma-type BRAF in the early stages of its development.